[Good News] Pioglitazone and Metformin Hydrochloride Tablets Preliminarily Selected in the 12th National Centralized Drug Procurement

2026/08/04

Recently, Beijing Beilu Pharmaceutical Co., Ltd. participated in the bidding process for the 12th National Centralized Drug Procurement organized by the Joint Procurement Office. We are pleased to announce that the Company's Pioglitazone and Metformin Hydrochloride Tablets has been preliminarily selected.

Basic Information of the Preliminarily Selected Product

Preliminarily Selected Company	Preliminarily Selected Product Name	Indications	Submitted Specification
Beijing Beilu Pharmaceutical Co., Ltd.	Pioglitazone and Metformin Hydrochloride Tablets (Oral Immediate-Release Dosage Form)	Indicated as an adjunct to diet and exercise to improve glycemic control in adults type 2 diabetes mellitus who are treated with a combination of pioglitazone hydrochloride and metformin hydrochloride, or whose blood glucose is inadequately controlled on metformin hydrochloride alone.	Each tablet contains 15mg of pioglitazone hydrochloride (calculated as C₁₉H₂₀N₂O₃S) and 500mg of metformin hydrochloride.

PREV : No information

NEXT : Join Beilu Pharma at CPHI Milan 2026: Discover Advanced Pharmaceutical Solutions

References

Related Products

Gadobutrol Injection/API

Gadopentetate Dimeglumine

Iomeprol Injection

Related Beilu News

Gadobutrol Injection Proposed for Selection in the 11th National Drug Centralized Procurement
October 30, 2025Recently, Beijing Beilu Pharmaceutical Co., Ltd. participated in the bidding work for the eleventh batch of national drug centralized procurement organized by Chinese National Organization for Drug Pr...view
Hichi Pharmaceutical, a Subsidiary of Beilu Pharmaceutical, Receives Approval for Iomeprol API
August 15, 2025Recently, Hichi Pharmaceutical's Iomeprol API has received the "Approval Notice for the Market Application of Chemical APIs" from the NMPA. This is another blockbuster product approved f...view
Beilu Pharmaceutical Has Won the
June 8, 2023Recently, the Beijing Municipal Drug Administration and the Beijing Municipal Health Commission issued a notification on "Commending Outstanding Units and Individuals in the Monitoring of Adverse...view
Beilu Pharmaceutical has Won the '2022 China Top 500 Corporate Philanthropy' Award!
February 24, 2023Recently, the "Wealth and Responsibility - Values of Enterprises" 2022 China Top 500 Charity List Conference was held in Chongqing. Since its inclusion in 2021, Beilu Pharmaceutical has been...view
Anti Anxiety Drugs More Effective Than Blood Pressure Medication for Mood-induced Hypertension
July 5, 2022Young and middle-aged people face more problems in life, work, and emotion. So they are prone to anxiety, which can lead to high blood pressure. Therefore, it is important to control and relieve the a...view
Iohexol Injection of Beilu Pharmaceutical Receives MA in the EU
April 11, 2025Recently, Beijing Beilu Pharmaceutical Co., Ltd. received the "Marketing Authorization" (MA) issued by the Netherlands Medicines Evaluation Board (MEB) in accordance with the relevant regula...view

[Good News] Pioglitazone and Metformin Hydrochloride Tablets Preliminarily Selected in the 12th National Centralized Drug Procurement

Gadobutrol Injection Proposed for Selection in the 11th National Drug Centralized Procurement

Hichi Pharmaceutical, a Subsidiary of Beilu Pharmaceutical, Receives Approval for Iomeprol API

Beilu Pharmaceutical Has Won the

Beilu Pharmaceutical has Won the '2022 China Top 500 Corporate Philanthropy' Award!

Anti Anxiety Drugs More Effective Than Blood Pressure Medication for Mood-induced Hypertension

Iohexol Injection of Beilu Pharmaceutical Receives MA in the EU